Marker Therapeutics (MRKR) Net Margin (2016 - 2025)
Marker Therapeutics' (MRKR) quarterly Net Margin came in at 155.73% in Q4 2025, up 1248.0% year-over-year from 11.55% in Q4 2024, and up 3.93% quarter-over-quarter from 162.11% in Q3 2025.
Powered by 
Analysis
Marker Therapeutics (MRKR) Net Margin (2016 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has reported Net Margin for 9 consecutive years, with 155.73% the latest figure, recorded in Q4 2025.
- On a quarterly basis, Net Margin rose 1248.0% year-over-year to 155.73% in Q4 2025; TTM through Dec 2025 was 380.82%, a 23690.0% decrease from a year earlier, with the FY2025 full-year figure at 271.28%, down 14325.0% from the prior year.
- Net Margin was 155.73% for Q4 2025 at Marker Therapeutics, up from 162.11% in the prior quarter.
- Over five years, Net Margin peaked at 574.97% in Q2 2023 and troughed at 1373.6% in Q1 2025.
- A 4-year average of 443.73% and a median of 192.34% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin surged 174437 bps in 2023 and slumped 118126 bps in 2025, its largest moves.
- Over 4 years, Net Margin stood at 136.3% in 2022, then slumped by 749 bps to 1157.57% in 2023, then surged by 85 bps to 168.21% in 2024, then advanced by 7 bps to 155.73% in 2025.
- The last three Net Margin figures came in at 155.73% (Q4 2025), 162.11% (Q3 2025), and 579.92% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 45.94% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -895.73% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -47.62% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 20.08% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -1,387.76% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -25,036.33% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -1.22% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 2.88% |
| 10 | Marker Therapeutics | 23.37 Mn | 11.44 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -155.73% |
| Sep 30, 2025 | -162.11% |
| Jun 30, 2025 | -579.92% |
| Mar 31, 2025 | -1,373.60% |
| Dec 31, 2024 | -168.21% |
| Sep 30, 2024 | -119.84% |
| Jun 30, 2024 | -109.63% |
| Mar 31, 2024 | -192.34% |
| Sep 30, 2023 | -1,157.57% |
| Jun 30, 2023 | 574.97% |
| Mar 31, 2023 | -198.70% |
| Dec 31, 2022 | -136.30% |
| Sep 30, 2022 | -692.26% |
| Jun 30, 2022 | -1,169.40% |
| Mar 31, 2022 | -1,015.39% |
| Dec 31, 2020 | -25,612.61% |
| Jun 30, 2020 | -1,358.59% |
| Dec 31, 2019 | -2,428.38% |
| Jun 30, 2018 | -2,268.90% |
| Sep 30, 2017 | -2,179.30% |